Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Share-based Compensation (2011 - 2026)

Updated

Grace Therapeutics' Share-based Compensation was $197,000 in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 4.4% from $206,000 a year earlier but up 87.6% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Share-based Compensation (2011 - 2026) Analysis & Trends

On a trailing twelve-month basis, Grace Therapeutics' Share-based Compensation was $592,000 through Sep 30, 2026, down 25.8% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $798,000, up 9.3% from FY2025.

  • Share-based Compensation shows a five-year compound annual growth rate of -7.4% (FY2021 to FY2026).
  • In earlier fiscal years, Share-based Compensation was $730,000 in FY2025 (-20.0%), $913,000 in FY2024 (-49.6%), $1.81 million in FY2023 (+35.5%) and $1.34 million in FY2022 (+13.9%).
  • Quarterly Share-based Compensation has moved between $443.00 (fiscal Q3 2023) and $616,000 (fiscal Q4 2022) over five years.
  • Compared with a year earlier, Share-based Compensation was higher in three of the last eight quarters, with an average decline of 15.9%.
  • The best year-over-year quarter for Share-based Compensation over five years was fiscal Q4 2022 (growth of 260.2%); the worst was fiscal Q3 2023 (a decline of 99.9%).
  • Per Business Quant data, GRCE's Share-based Compensation in the three fiscal quarters before Q2 2027 was $105,000 (Q1 2027), $182,000 (Q4 2026) and $108,000 (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 200.00 Mn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 357.00 Mn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 160.00 Mn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 369.00 Mn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 128.00 Mn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 234.00 Mn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 362.00 Mn
10 Grace Therapeutics 35.10 Mn -35.61 Mn - 197,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 197,000.00
Jun 30, 2026 105,000.00
Mar 31, 2026 182,000.00
Dec 31, 2025 108,000.00
Sep 30, 2025 206,000.00
Jun 30, 2025 302,000.00
Mar 31, 2025 130,000.00
Dec 31, 2024 160,000.00
Sep 30, 2024 202,000.00
Jun 30, 2024 238,000.00
Mar 31, 2024 229,000.00
Dec 31, 2023 326,000.00
Sep 30, 2023 280,000.00
Jun 30, 2023 78,000.00
Mar 31, 2023 322,000.00
Dec 31, 2022 443.00
Sep 30, 2022 582.00
Jun 30, 2022 464,000.00
Mar 31, 2022 616,000.00
Dec 31, 2021 454,000.00
API Access

Grace Therapeutics Share-based Compensation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation&ticker=GRCE&period=max&api_key=YOUR_API_KEY